The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.
 
Ana-Alicia Beltran-Bless
No Relationships to Disclose
 
Gregory Russell Pond
Employment - Roche Canada (I)
Stock and Other Ownership Interests - Roche Canada (I)
Honoraria - AstraZeneca; AstraZeneca
Consulting or Advisory Role - Merck; Profound Medical; Takeda
 
Jane Bayani
Honoraria - NanoString Technologies; Thermo Fisher Scientific
Research Funding - Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer (Inst); Patent (applied): 95-Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer (Patent Title), National Phase Application, Patent application number 3007118 (Country of Filing: Canada – Patent Application Date: 06/01/18); 15/781 (Inst); Patent (applied): A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer (Invention Title), PCT International Application No.: PCT/CA2021/050837, International Filing Date: June 18, 2021 (Inst); Patent (granted): 95-Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer (Patent Title), National Phase Application, Patent number: 2016368696 (Country: Australia, Date: Mar. 10, 2022); 2016800813945 (China, Mar. 18, 2022) (Inst)
 
Sarah Barker
No Relationships to Disclose
 
Melanie Spears
No Relationships to Disclose
 
Elizabeth Mallon
No Relationships to Disclose
 
Karen J Taylor
Research Funding - Exact Sciences (Inst)
 
Annette Hasenburg
Honoraria - AstraZeneca; Celgene; GlaxoSmithKline; LEO Pharma; MedConcept; Medicultus Kassel; Pfizer; Promedicis ; Roche; SoftConsultGroup; Streamedup!; Tesaro
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/MSD; LEO Pharma; PharmaMar; Promedicis; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; MedConcept
 
Christos Markopoulos
Honoraria - Exact Sciences
Consulting or Advisory Role - Exact Sciences
Travel, Accommodations, Expenses - Exact Sciences
 
Luc Yves Dirix
No Relationships to Disclose
 
Caroline M. Seynaeve
No Relationships to Disclose
 
Cornelis J.H. Van De Velde
No Relationships to Disclose
 
Daniel William Rea
Honoraria - daiiachi Sankyo; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Genomic Health; MSD Oncology
Research Funding - bioTheranostics (Inst); Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; eisai; Novartis; Pfizer
 
Lisa Vandermeer
No Relationships to Disclose
 
John Frederick Hilton
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck; Novartis; Pfizer; Puma Biotechnology
 
John Bartlett
Leadership - MedcomXchange
Honoraria - bioTheranostics; MedcomXchange; NanoString Technologies; Oncology Education
Consulting or Advisory Role - AstraZeneca; BioNTech; bioTheranostics; Cerca Biotech; Herbert Smith Freehills Paris; Insight Genetics; OncoCyte; oncoXchange; Ontario Institute for Cancer Research; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Exact Sciences; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019 (Inst); John Bartlett currently has 3 granted patents: -CIN4 predicts benefit from anthracycline (Invention Title), National Phase Application, Patent number: 11214836 (Country: United States, Date: Jan. 4, 2022); 3169815 (Europe, Dec. 23, 2020) -Targeting the H (Inst); John Bartlett currently has 6 pending patents: -CIN4 predicts benefit from anthracycline, National Phase Application, (Canada, Jan. 11, 2017) -Systems, Devices and Methods for Constructing and Using a Biomarker, National Phase Application, 15/328,108 (Un (Inst)
Travel, Accommodations, Expenses - bioTheranostics; Breast Cancer Society of Canada; NanoString Technologies
 
Mark J. Clemons
Travel, Accommodations, Expenses - Pfizer